Isolation and characterization of a monomethioninesulfoxide variant of interferon alpha-2b

被引:29
|
作者
Gitlin, G [1 ]
Tsarbopoulos, A [1 ]
Patel, ST [1 ]
Sydor, W [1 ]
Pramanik, BN [1 ]
Jacobs, S [1 ]
Westreich, L [1 ]
Mittelman, S [1 ]
Bausch, JN [1 ]
机构
[1] SCHERING PLOUGH CORP,RES INST,KENILWORTH,NJ 07033
关键词
protein mapping; mass spectrometry; methionine oxidation;
D O I
10.1023/A:1016059902645
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
Purpose. To isolate and characterize a monomethioninesulfoxide variant of the commercially available therapeutic protein interferon alpha-2b. Methods. The methionine (Met)-oxidized variant was isolated by reverse-phase high performance liquid chromatography and characterized by SDS-PAGE, peptide mapping and mass spectrometric analysis of the trypsin/V8-generated peptide fragments. The biological and immunological activities of the isolated variant were also evaluated. Results. The rHuIFN alpha-2b variant was found to contain a Met sulfoxide residue at position ill of the rHuIFN alpha-2b molecule. The far-UV CD spectra showed a slight loss of alpha-helical content and an increase in the beta-sheet contribution. The CD spectra indicate that both chromatographic conditions and Met oxidation contribute to the observed secondary structure changes. Both interferon alpha-2b main component and its methionine-oxidized variant showed different reactivity to monoclonal antibodies employed in immunoassays for the protein. Conclusions. A monomethioninesulfoxide rHuIFN alpha-2b variant was found to be present in the rHuIFN alpha-2b bulk drug substance in solution. The Met(111) residue was identified as Met sulfoxide by comparative tryptic/V8 mapping and mass spectrometric analysis. Nevertheless, the oxidation of the Met(111) residue did not seem to have a detectable effect on the biological activity of the molecule.
引用
收藏
页码:762 / 769
页数:8
相关论文
共 50 条
  • [1] ALPHA-2B INTERFERON AND HYPOTHYROIDISM
    JAVIER, RM
    SIBILIA, J
    KUNTZ, JL
    SCHLIENGER, JL
    ASCH, L
    REVUE DU RHUMATISME, 1992, 59 (7-8): : 501 - 501
  • [2] INTERFERON ALPHA-2B IN THE TREATMENT OF MYELOFIBROSIS
    FURESI, L
    PASINI, FL
    FORCONI, S
    HAEMATOLOGICA, 1990, 75 (06) : 587 - 589
  • [3] INTRAVENTRICULAR ALPHA-2B INTERFERON FOR SSPE
    MITCHELL, WG
    CRAWFORD, TO
    NEUROLOGY, 1987, 37 (12) : 1884 - 1884
  • [4] Trichomegaly following treatment with interferon alpha-2b
    Hernández-Núnéz, A
    Fernández-Herrera, J
    Buceta, LR
    García-Díez, A
    LANCET, 2002, 359 (9312): : 1107 - 1107
  • [5] Comparative Effects of Interferon Alpha-2b and Pegylated Interferon Alpha-2b on Menstrual Cycles and Ovarian Hormones in Cynomolgus Monkeys
    Enright, Brian P.
    Compton, David R.
    Collins, Nathaniel
    Davis, Thomas
    McIntyre, Barry S.
    BIRTH DEFECTS RESEARCH PART B-DEVELOPMENTAL AND REPRODUCTIVE TOXICOLOGY, 2009, 86 (01) : 29 - 39
  • [6] TREATMENT OF ESSENTIAL THROMBOCYTHEMIA WITH INTERFERON ALPHA-2B
    MAY, D
    WANDL, UB
    NIEDERLE, N
    LANCET, 1989, 1 (8629): : 96 - 96
  • [7] Ineffective treatment of keloids with interferon alpha-2b
    Davison, SP
    Mess, S
    Kauffman, LC
    Al-Attar, A
    PLASTIC AND RECONSTRUCTIVE SURGERY, 2006, 117 (01) : 247 - 252
  • [8] Helix BioPharma and Topical Interferon Alpha-2b
    不详
    JOURNAL OF DRUGS IN DERMATOLOGY, 2010, 9 (06) : 723 - 724
  • [9] Treatment of eosinophilic gastroenteritis with interferon alpha-2b
    Crockett, RE
    Ledford, DK
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2002, 109 (01) : S206 - S206
  • [10] Interferon alpha-2B in juvenile hyaline fibromatosis
    Ruiz-Maldonado, R
    Durán-McKinster, C
    Sáez-de-Ocariz, M
    Calderón-Elvir, C
    Yamazaki-Nakashimada, MA
    Orozco-Covarrubias, L
    CLINICAL AND EXPERIMENTAL DERMATOLOGY, 2006, 31 (03) : 478 - 479